ArticleFrontiers in neuroscience2014
Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia.
Article in Frontiers in neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- The role of C957T, TaqI and Ser311Cys polymorphisms of the DRD2 gene in schizophrenia: systematic review and meta-analysis.Behavioral and brain functions : BBF · 2016Pooled it
- Evaluation of association of common variants in HTR1A and HTR5A with schizophrenia and executive function.Scientific reports · 2016Trial
- Post-mortem brain analysis reveals altered monoaminergic system in the dorsolateral prefrontal cortex and hippocampus in chronic schizophrenia.Schizophrenia (Heidelberg, Germany) · 2026Article
- Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024.F1000Research · 2025Article
- Spatial differences in gene expression across the dorsal raphe nucleus in a model of early Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2025Article
- Interaction of serotonin/GLP-1 circuitry in a dual preclinical model for psychiatric disorders and metabolic dysfunction.Psychiatry research · 2024Article
- Serotonergic dysfunction may mediate the relationship between alcohol consumption and Alzheimer's disease.Pharmacological research · 2024Review
- Quetiapine improves sensorimotor gating deficit in a sleep deprivation-induced rat model.Sleep and biological rhythms · 2024Article
- GDNF and miRNA-29a as biomarkers in the first episode of psychosis: uncovering associations with psychosocial factors.Frontiers in psychiatry · 2024Article
- Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia.CNS drugs · 2023Review
- Biopsychology of Physical Activity in People with Schizophrenia: An Integrative Perspective on Barriers and Intervention Strategies.Neuropsychiatric disease and treatment · 2022Article
- Simultaneous serotonin and dopamine monitoring across timescales by rapid pulse voltammetry with partial least squares regression.Analytical and bioanalytical chemistry · 2021Article
- Gastric Serotonin Biosynthesis and Its Functional Role in L-Arginine-Induced Gastric Proton Secretion.International journal of molecular sciences · 2021Article
- Article
- Synthesis and biological investigations of 3β-aminotropane arylamide derivatives with atypical antipsychotic profile.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2018Article
- Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.Molecular brain · 2017Review
- Maternal high-fat diet programming of the neuroendocrine system and behavior.Hormones and behavior · 2015Review
- Association between the dopamine D4 receptor gene exon III variable number of tandem repeats and political attitudes in female Han Chinese.Proceedings. Biological sciences · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Negative symptoms (e.g., decreased spontaneity, social withdrawal, blunt affect) and disturbances of cognitive function (e.g., several types of memory, attention, processing speed, executive function, fluency) provide a major determinant of long-term outcome in patients with schizophrenia. Specifically, motivation deficits, a type of negative symptoms, have been attracting interest as (1) a moderator of cognitive performance in schizophrenia and related disorders, and (2) a modulating factor of cognitive enhancers/remediation. These considerations suggest the need to clarify neurobiological substrates regulating motivation. Genetic studies indicate a role for the monoamine systems in motivation and key cognitive domains. For example, polymorphism of genes encoding catecholamine-O-methyltransferase, an enzyme catabolizing dopamine (DA), affects performance on tests of working memory and executive function in a phenotype (schizophrenia vs. healthy controls)-dependent fashion. On the other hand, motivation to maximize rewards has been shown to be influenced by other genes encoding DA-related substrates, such as DARPP-32 and DA-D2 receptors. Serotonin (5-HT) receptors may also play a significant role in cognitive and motivational disabilities in psychoses and mood disorders. For example, mutant mice over-expressing D2 receptors in the striatum, an animal model of schizophrenia, exhibit both decreased willingness to work for reward and up-regulation of 5-HT2C receptors. Taken together, genetic predisposition related to 5-HT receptors may mediate the diversity of incentive motivation that is impaired in patients receiving biological and/or psychosocial treatments. Thus, research into genetic and neurobiological measures of motivation, in association with 5-HT receptors, is likely to facilitate intervention into patients seeking better social consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.